(vianews) - tubize-fin (tub.br) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| tubize-fin (tub.br) | €71.50 | 1.26% | 4.93% |
| ipsen (ipn.pa) | €107.00 | 1.08% | 12.52% |
| sartorius sted bio (dim.pa) | €242.10 | 0.62% | 18.66% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. tubize-fin (tub.br)
1.26% forward dividend yield and 4.93% return on equity
financière de tubize sa operates as a mono holding company whose sole investment is a stake in ucb which is a biopharma company in belgium. the company is based in brussels, belgium.
earnings per share
as for profitability, tubize-fin has a trailing twelve months eps of €2.
pe ratio
tubize-fin has a trailing twelve months price to earnings ratio of 35.75. meaning, the purchaser of the share is investing €35.75 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.93%.
yearly top and bottom value
tubize-fin's stock is valued at €71.50 at 11:30 est, way below its 52-week high of €79.90 and way above its 52-week low of €60.80.
dividend yield
as claimed by morningstar, inc., the next dividend payment is on may 3, 2023, the estimated forward annual dividend rate is 0.86 and the estimated forward annual dividend yield is 1.26%.
volatility
tubize-fin's last week, last month's, and last quarter's current intraday variation average was 1.20%, 0.42%, and 1.27%.
tubize-fin's highest amplitude of average volatility was 1.48% (last week), 1.60% (last month), and 1.27% (last quarter).
moving average
tubize-fin's worth is above its 50-day moving average of €66.40 and above its 200-day moving average of €71.35.more news about tubize-fin.
2. ipsen (ipn.pa)
1.08% forward dividend yield and 12.52% return on equity
ipsen s.a. operates as a biopharmaceutical company worldwide. the company provides drugs in the areas of oncology, neuroscience, and rare diseases. it offers somatuline for neuroendocrine tumors and acromegaly; dysport for motor muscular disorders and medical aesthetics; decapeptyl for the treatment of advanced metastatic prostate cancer; cabometyx for renal cell and second-line hepatocellular carcinoma; onivyde for second-line metastatic pancreatic cancer; and tazverik to treat third-line follicular lymphoma. the company also provides nutropinaq for growth failure in children due to growth hormone (gh) deficiency, turner syndrome or chronic renal insufficiency, and gh deficiency in adults; and increlex for growth failure in children and adolescents. in addition, it offers xermelo for the treatment of carcinoid syndrome; and cometriq to treat medullary thyroid cancer. ipsen s.a. has agreements with debiopharm; exelixis; galderma; blueprint medicines; tersera therapeutics; rhythm pharmaceuticals; teijin; schwabe; bakx therapeutics inc.; and exicure. the company was founded in 1929 and is headquartered in boulogne-billancourt, france.
earnings per share
as for profitability, ipsen has a trailing twelve months eps of €4.89.
pe ratio
ipsen has a trailing twelve months price to earnings ratio of 21.88. meaning, the purchaser of the share is investing €21.88 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.52%.
yearly top and bottom value
ipsen's stock is valued at €107.00 at 11:30 est, way under its 52-week high of €130.70 and way above its 52-week low of €94.85.
revenue growth
year-on-year quarterly revenue growth grew by 8.4%, now sitting on 3.28b for the twelve trailing months.
volume
today's last reported volume for ipsen is 5954 which is 92.21% below its average volume of 76468.
more news about ipsen.
3. sartorius sted bio (dim.pa)
0.62% forward dividend yield and 18.66% return on equity
sartorius stedim biotech s.a. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. the company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. it also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. in addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. it serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. the company was founded in 1870 and is headquartered in aubagne, france. sartorius stedim biotech s.a. is a subsidiary of sartorius ag.
earnings per share
as for profitability, sartorius sted bio has a trailing twelve months eps of €5.
pe ratio
sartorius sted bio has a trailing twelve months price to earnings ratio of 48.42. meaning, the purchaser of the share is investing €48.42 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.66%.
earnings before interest, taxes, depreciation, and amortization
sartorius sted bio's ebitda is 8.44.
yearly top and bottom value
sartorius sted bio's stock is valued at €242.10 at 11:30 est, way below its 52-week high of €358.80 and way higher than its 52-week low of €160.55.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, sartorius sted bio's stock is considered to be oversold (<=20).
revenue growth
year-on-year quarterly revenue growth declined by 24.1%, now sitting on 2.96b for the twelve trailing months.
more news about sartorius sted bio.